Hypoglycemic version of semaglutide cause blindness? Novo Nordisk: Very few confirmed cases

Semaglutide cause blindness? Recently, a research paper published in the Journal of the American Medical Association Ophthalmology pointed out that some patients have developed eye complications after using NovoNordisk Ozempic (hypoglycemic version of semaglutide) or Eli Lilly’s Mounjaro (hypoglycemic version of tirzepatide). Both drugs belong to the highly active GLP-1 class.
Regarding the above content, Novo Nordisk told The Paper that as stated in the original text, the study cannot confirm a causal relationship between such drugs, including semaglutide, and the reported ocular complications. Non arteritic anterior ischemic optic neuropathy (NAION) is a very rare eye disease. According to the approved instructions, NAION is not an adverse drug reaction of semaglutide .
Novo Nordisk explained that they analyzed randomized controlled clinical trials of GLP-1 receptor agonists they possess, including blind evaluations of ophthalmologists to confirm the diagnosis of NAION. Analysis has found that there are very few cases of NAION diagnosed by ophthalmologists, and there is no imbalance problem with GLP-1 products that are detrimental to Novo Nordisk. Semaglutide cause blindness is without scientific principles.